GITNUXREPORT 2026

Endometriosis Infertility Statistics

Endometriosis is a leading cause of female infertility worldwide.

Min-ji Park

Research Analyst focused on sustainability and consumer trends.

First published: Feb 13, 2026

Our Commitment to Accuracy

Rigorous fact-checking · Reputable sources · Regular updatesLearn more

Statistic 1

In endometriosis patients, spontaneous pregnancy rate is 40-60% within 1 year vs 80% in fertile.

Statistic 2

IVF success rate (live birth) 24% per cycle in mild endometriosis vs 31% controls.

Statistic 3

Cumulative live birth rate after 3 IVF cycles: 55% for stage I/II endometriosis.

Statistic 4

IUI pregnancy rate 8.6% per cycle in minimal endometriosis, similar to unexplained infertility.

Statistic 5

In women with endometriomas >3cm, IVF live birth rate drops to 18% per cycle.

Statistic 6

GnRH agonist pretreatment before IVF improves pregnancy rates by 15% in severe cases.

Statistic 7

Frozen embryo transfer in endometriosis yields 35% live birth vs 28% fresh.

Statistic 8

Donor oocyte IVF success 50% in advanced endometriosis age >38.

Statistic 9

Mild stimulation IVF protocols achieve 22% CPR in young endometriotic women.

Statistic 10

After hysteroscopic polyp removal in endometriosis, pregnancy rate rises to 45%.

Statistic 11

IVF miscarriage rate 20% higher (25% vs 20%) in endometriosis patients.

Statistic 12

Natural cycle IVF: 12% ongoing pregnancy rate in mild endometriosis.

Statistic 13

PGT-A in endometriosis improves implantation by 10% to 40% per euploid transfer.

Statistic 14

Clomiphene + IUI: 10% pregnancy/cycle in stage I endometriosis.

Statistic 15

Long GnRH agonist protocol: 30% clinical pregnancy in moderate endometriosis.

Statistic 16

After 6 months OCP suppression, IVF success increases 12%.

Statistic 17

Blastocyst transfer yields 28% LBR vs 22% day 3 in endometriomas.

Statistic 18

IVF with ICSI: fertilization rate 65% in severe endometriosis.

Statistic 19

Cumulative incidence of live birth after 24 months ART: 65% in endometriosis.

Statistic 20

Letrozole trigger in IVF improves oocyte yield by 20% in poor responders with endometriosis.

Statistic 21

Laparoscopic adhesiolysis prior to IVF boosts pregnancy rate to 35%.

Statistic 22

In vitro maturation (IVM) success 25% in endometrioma patients avoiding aspiration.

Statistic 23

Dual trigger (hCG + GnRH) increases LBR by 8% to 32%.

Statistic 24

Endometrial scratching before IVF: no benefit, 28% vs 29% pregnancy.

Statistic 25

Time-lapse imaging selects embryos with 38% implantation in endometriosis.

Statistic 26

Distorted pelvic anatomy in 70% of severe endometriosis leads to infertility.

Statistic 27

Inflammatory cytokines (IL-6, TNF-α) elevated 3-5 fold in endometriotic fluid impair oocyte quality.

Statistic 28

Endometrial receptivity reduced by 40% due to HOXA10 downregulation in endometriosis.

Statistic 29

Oxidative stress markers (ROS) 2x higher in follicular fluid of endometriotic women.

Statistic 30

Impaired implantation rates by 25-30% from altered integrin expression in eutopic endometrium.

Statistic 31

Progesterone resistance in 80% of endometriosis cases disrupts decidualization.

Statistic 32

Angiogenic factors (VEGF) upregulated 4-fold, causing adhesions affecting tubal function.

Statistic 33

Reduced AMH levels by 20-30% in women with endometriomas correlate with poor ovarian reserve.

Statistic 34

Tubal peristalsis impaired in 60% of mild endometriosis via prostaglandin dysregulation.

Statistic 35

Sperm binding to zona pellucida decreased 50% in peritoneal fluid exposure from endometriosis.

Statistic 36

Endometrial stem cell dysfunction leads to 35% lower implantation success.

Statistic 37

Macrophage activation in pelvis releases factors reducing oocyte maturation by 40%.

Statistic 38

Bcl-2 apoptosis inhibition in endometriotic lesions affects follicular atresia rates.

Statistic 39

Glycodelin-A expression altered, reducing immunosuppression at implantation site by 45%.

Statistic 40

Matrix metalloproteinases (MMP-2/9) elevated 3x, causing ectopic implantation risks.

Statistic 41

LIF (leukemia inhibitory factor) downregulated 50% in secretory phase endometrium.

Statistic 42

Hyperestrogenism in endometriosis shortens follicular phase, impairing ovulation in 25%.

Statistic 43

Nerve growth factor (NGF) overexpression causes pelvic pain and dysmenorrhea linked to infertility.

Statistic 44

Endometrial microbiome dysbiosis with Lactobacillus reduction affects receptivity.

Statistic 45

Iron overload in endometriotic cysts induces oxidative damage to gametes.

Statistic 46

PDGF signaling pathway hyperactivation impairs decidual stromal cell differentiation.

Statistic 47

Reduced NK cell cytotoxicity in endometrium by 30% promotes implantation failure.

Statistic 48

COX-2 mediated prostaglandin E2 excess inhibits corpus luteum function.

Statistic 49

Epigenetic silencing of ER-β in 70% of cases leads to estrogen hypersensitivity.

Statistic 50

Follistatin-like 3 (FSTL3) overexpression correlates with poor oocyte retrieval.

Statistic 51

GnRH antagonists post-surgery: 35% conception within 12 months.

Statistic 52

Dienogest 2mg daily: 40% pain relief, 25% improved fertility prognosis.

Statistic 53

Elagolix 150mg: suppresses lesions 50%, delays infertility progression.

Statistic 54

Progestins (desogestrel): 60% amenorrhea, preserves ovarian reserve for fertility.

Statistic 55

Aromatase inhibitors + OCP: 55% cyst reduction, better IVF outcomes.

Statistic 56

Levonorgestrel-IUS: 70% endometrial suppression, 30% spontaneous pregnancy post-removal.

Statistic 57

Danazol short-term: 50% lesion regression, fertility rate 40% post-treatment.

Statistic 58

Combined OCP continuous: reduces recurrence 45%, aids fertility planning.

Statistic 59

Cabergoline adjunct: prevents adhesion post-op, 35% higher pregnancy.

Statistic 60

Pentoxifylline 400mg tid: improves IVF success 15% via anti-inflammatory.

Statistic 61

Omega-3 supplementation: 25% lower dysmenorrhea, better fertility prognosis.

Statistic 62

N-acetyl cysteine 600mg: cyst size reduction 20%, preserves fertility.

Statistic 63

Long-term prognosis: 50% of treated women conceive naturally within 2 years.

Statistic 64

Relugolix combo: 75% lesion reduction, minimal bone loss, fertility deferral.

Statistic 65

Melatonin 3mg: antioxidant, 30% improved oocyte quality in IVF.

Statistic 66

Curcumin 500mg: reduces inflammation markers 40%, aids fertility.

Statistic 67

Post-treatment recurrence 20-40% at 5 years with medical therapy.

Statistic 68

Dienogest vs GnRH: similar efficacy, better fertility preservation.

Statistic 69

Lifestyle (diet/exercise): 15% fertility improvement in mild cases.

Statistic 70

Acupuncture adjunct: 20% higher pregnancy rates post-treatment.

Statistic 71

Immunomodulators (lupron + steroids): 50% deep lesion shrinkage.

Statistic 72

Prognosis after 40: 20% natural conception with medical optimization.

Statistic 73

Vitamin D supplementation: corrects deficiency in 70%, improves IVF 10%.

Statistic 74

Approximately 30-50% of women with endometriosis experience infertility, with endometriosis accounting for 25-40% of female infertility cases.

Statistic 75

In a cohort of 1,236 women with endometriosis, 40% presented with infertility as the primary complaint.

Statistic 76

Endometriosis is found in 24-50% of women undergoing laparoscopy for infertility evaluation.

Statistic 77

Among infertile women, the prevalence of minimal/mild endometriosis is 17%, moderate/severe is 23%.

Statistic 78

Endometriosis affects 10% of reproductive-age women, but up to 50% of those with infertility.

Statistic 79

In a meta-analysis of 23 studies, pooled prevalence of endometriosis in infertile women was 25% (95% CI: 19-32%).

Statistic 80

African American women with endometriosis have higher infertility rates at 44% compared to 30% in Caucasians.

Statistic 81

Endometriosis-related infertility affects 176 million women worldwide annually.

Statistic 82

In subfertile women under 35, endometriosis prevalence is 32% via laparoscopy.

Statistic 83

35% of women with deep infiltrating endometriosis report infertility.

Statistic 84

Infertility rates rise to 67% in stage III/IV endometriosis per ASRM classification.

Statistic 85

In a UK study of 5,000 infertile couples, 12% had endometriosis diagnosed.

Statistic 86

Adolescent girls with endometriosis show 20% infertility risk by early adulthood.

Statistic 87

Endometriosis prevalence in women with pelvic pain and infertility is 40-60%.

Statistic 88

In Italian cohort, 28.5% of infertile women had endometriosis.

Statistic 89

Global estimate: 190 million women have endometriosis, 40% infertile.

Statistic 90

In PCOS-overlap with endometriosis, infertility jumps to 55%.

Statistic 91

Nulliparous women with endometriosis have 45% infertility rate.

Statistic 92

In Asia, endometriosis infertility prevalence is 15-20% of cases.

Statistic 93

US data: 1 in 10 women with endometriosis seek infertility treatment.

Statistic 94

Stage I endometriosis linked to 10-15% reduced fecundity in infertile women.

Statistic 95

European studies show 30% infertility in endometriosis patients aged 25-35.

Statistic 96

In Brazilian study of 400 women, 38% with endometriosis were infertile.

Statistic 97

Hispanic women with endometriosis have 35% infertility prevalence.

Statistic 98

Overweight BMI (>25) in endometriosis doubles infertility risk to 50%.

Statistic 99

Family history of endometriosis increases infertility odds by 2.5-fold to 40%.

Statistic 100

In vitro diagnostics show 25% endometriosis in unexplained infertility.

Statistic 101

Australian data: 1 in 8 infertile women have endometriosis.

Statistic 102

Peritoneal fluid analysis in 500 infertile: 29% endometriosis positive.

Statistic 103

Canadian registry: 22% of IVF cycles for endometriosis infertility.

Statistic 104

Laparoscopic excision of endometriosis improves natural pregnancy rates to 60% post-op.

Statistic 105

Ablation vs excision: excision yields 75% pain relief and 50% fertility improvement.

Statistic 106

Deep infiltrating endometriosis (DIE) surgery: 52% spontaneous pregnancy rate within 1 year.

Statistic 107

Cystectomy for endometriomas >4cm: recurrence 20%, fertility preserved in 70%.

Statistic 108

Rectovaginal endometriosis resection: 40% achieve pregnancy without ART.

Statistic 109

Microsurgical adhesiolysis increases tubal patency to 65%, pregnancy 30%.

Statistic 110

Robotic-assisted laparoscopy for stage IV: 55% fertility rate post-op.

Statistic 111

Bowel resection in DIE: complication rate 10%, pregnancy rate 45%.

Statistic 112

Ureterolysis during endometriosis surgery restores function in 85%, aids fertility.

Statistic 113

Hysteroscopic metroplasty for T-shaped uterus in endometriosis: 50% term delivery.

Statistic 114

Salpingectomy for hydrosalpinx in endometriosis: IVF success up 25% post-op.

Statistic 115

Segmental resection for colorectal endometriosis: 60% dyspareunia relief, 35% pregnancy.

Statistic 116

Laparoscopic uterosacral ligament resection: 70% pain reduction, fertility benefit 40%.

Statistic 117

Oophorectomy avoidance in unilateral endometrioma: preserves fertility in 80%.

Statistic 118

Nerve-sparing radical excision: maintains ovarian reserve, AMH drop <10%.

Statistic 119

Postoperative adhesion prevention with barriers: reduces reoperation 30%.

Statistic 120

Fertility-sparing cystectomy: recurrence 15% at 2 years, 65% conception rate.

Statistic 121

Multidisciplinary DIE surgery: 50% live birth rate in 2 years follow-up.

Statistic 122

Vaporization of ovarian endometriomas: preserves AMH better, pregnancy 45%.

Statistic 123

Shaving technique for DIE: 55% spontaneous pregnancies.

Statistic 124

Secondary surgery after initial laparoscopy: 30% additional fertility gain.

Statistic 125

Plasma energy for peritoneal lesions: 60% fertility improvement.

Statistic 126

Hysterectomy with BSO avoided: 75% maintain fertility potential post-conservative surgery.

Statistic 127

Ileocecal resection: 40% pregnancy rate, low morbidity 8%.

Statistic 128

Postoperative GnRH analogs: enhance pregnancy rates by 20% after surgery.

1/128

Sources

Trusted by 500+ publications

+497

Endometriosis isn't just a painful diagnosis—it’s a leading and often overlooked cause of infertility, affecting millions of women who may not realize their struggle to conceive is directly linked to this condition.

Key Takeaways

Approximately 30-50% of women with endometriosis experience infertility, with endometriosis accounting for 25-40% of female infertility cases.
In a cohort of 1,236 women with endometriosis, 40% presented with infertility as the primary complaint.
Endometriosis is found in 24-50% of women undergoing laparoscopy for infertility evaluation.
Distorted pelvic anatomy in 70% of severe endometriosis leads to infertility.
Inflammatory cytokines (IL-6, TNF-α) elevated 3-5 fold in endometriotic fluid impair oocyte quality.
Endometrial receptivity reduced by 40% due to HOXA10 downregulation in endometriosis.
In endometriosis patients, spontaneous pregnancy rate is 40-60% within 1 year vs 80% in fertile.
IVF success rate (live birth) 24% per cycle in mild endometriosis vs 31% controls.
Cumulative live birth rate after 3 IVF cycles: 55% for stage I/II endometriosis.
Laparoscopic excision of endometriosis improves natural pregnancy rates to 60% post-op.
Ablation vs excision: excision yields 75% pain relief and 50% fertility improvement.
Deep infiltrating endometriosis (DIE) surgery: 52% spontaneous pregnancy rate within 1 year.
GnRH antagonists post-surgery: 35% conception within 12 months.
Dienogest 2mg daily: 40% pain relief, 25% improved fertility prognosis.
Elagolix 150mg: suppresses lesions 50%, delays infertility progression.

Endometriosis is a leading cause of female infertility worldwide.

Fertility Treatment Outcomes

In endometriosis patients, spontaneous pregnancy rate is 40-60% within 1 year vs 80% in fertile.
IVF success rate (live birth) 24% per cycle in mild endometriosis vs 31% controls.
Cumulative live birth rate after 3 IVF cycles: 55% for stage I/II endometriosis.
IUI pregnancy rate 8.6% per cycle in minimal endometriosis, similar to unexplained infertility.
In women with endometriomas >3cm, IVF live birth rate drops to 18% per cycle.
GnRH agonist pretreatment before IVF improves pregnancy rates by 15% in severe cases.
Frozen embryo transfer in endometriosis yields 35% live birth vs 28% fresh.
Donor oocyte IVF success 50% in advanced endometriosis age >38.
Mild stimulation IVF protocols achieve 22% CPR in young endometriotic women.
After hysteroscopic polyp removal in endometriosis, pregnancy rate rises to 45%.
IVF miscarriage rate 20% higher (25% vs 20%) in endometriosis patients.
Natural cycle IVF: 12% ongoing pregnancy rate in mild endometriosis.
PGT-A in endometriosis improves implantation by 10% to 40% per euploid transfer.
Clomiphene + IUI: 10% pregnancy/cycle in stage I endometriosis.
Long GnRH agonist protocol: 30% clinical pregnancy in moderate endometriosis.
After 6 months OCP suppression, IVF success increases 12%.
Blastocyst transfer yields 28% LBR vs 22% day 3 in endometriomas.
IVF with ICSI: fertilization rate 65% in severe endometriosis.
Cumulative incidence of live birth after 24 months ART: 65% in endometriosis.
Letrozole trigger in IVF improves oocyte yield by 20% in poor responders with endometriosis.
Laparoscopic adhesiolysis prior to IVF boosts pregnancy rate to 35%.
In vitro maturation (IVM) success 25% in endometrioma patients avoiding aspiration.
Dual trigger (hCG + GnRH) increases LBR by 8% to 32%.
Endometrial scratching before IVF: no benefit, 28% vs 29% pregnancy.
Time-lapse imaging selects embryos with 38% implantation in endometriosis.

Fertility Treatment Outcomes Interpretation

Endometriosis stacks the deck against fertility at every turn, but a relentless mix of strategic surgery, clever protocol tweaks, and stubborn persistence can still coax the odds toward a live birth.

Mechanisms of Infertility

Distorted pelvic anatomy in 70% of severe endometriosis leads to infertility.
Inflammatory cytokines (IL-6, TNF-α) elevated 3-5 fold in endometriotic fluid impair oocyte quality.
Endometrial receptivity reduced by 40% due to HOXA10 downregulation in endometriosis.
Oxidative stress markers (ROS) 2x higher in follicular fluid of endometriotic women.
Impaired implantation rates by 25-30% from altered integrin expression in eutopic endometrium.
Progesterone resistance in 80% of endometriosis cases disrupts decidualization.
Angiogenic factors (VEGF) upregulated 4-fold, causing adhesions affecting tubal function.
Reduced AMH levels by 20-30% in women with endometriomas correlate with poor ovarian reserve.
Tubal peristalsis impaired in 60% of mild endometriosis via prostaglandin dysregulation.
Sperm binding to zona pellucida decreased 50% in peritoneal fluid exposure from endometriosis.
Endometrial stem cell dysfunction leads to 35% lower implantation success.
Macrophage activation in pelvis releases factors reducing oocyte maturation by 40%.
Bcl-2 apoptosis inhibition in endometriotic lesions affects follicular atresia rates.
Glycodelin-A expression altered, reducing immunosuppression at implantation site by 45%.
Matrix metalloproteinases (MMP-2/9) elevated 3x, causing ectopic implantation risks.
LIF (leukemia inhibitory factor) downregulated 50% in secretory phase endometrium.
Hyperestrogenism in endometriosis shortens follicular phase, impairing ovulation in 25%.
Nerve growth factor (NGF) overexpression causes pelvic pain and dysmenorrhea linked to infertility.
Endometrial microbiome dysbiosis with Lactobacillus reduction affects receptivity.
Iron overload in endometriotic cysts induces oxidative damage to gametes.
PDGF signaling pathway hyperactivation impairs decidual stromal cell differentiation.
Reduced NK cell cytotoxicity in endometrium by 30% promotes implantation failure.
COX-2 mediated prostaglandin E2 excess inhibits corpus luteum function.
Epigenetic silencing of ER-β in 70% of cases leads to estrogen hypersensitivity.
Follistatin-like 3 (FSTL3) overexpression correlates with poor oocyte retrieval.

Mechanisms of Infertility Interpretation

Endometriosis mounts a multi-front war on fertility, deploying everything from distorted anatomy and toxic biochemistry to hostile immune cells and a misbehaving endometrium, relentlessly sabotaging every delicate step from egg to embryo.

Medical Management and Prognosis

GnRH antagonists post-surgery: 35% conception within 12 months.
Dienogest 2mg daily: 40% pain relief, 25% improved fertility prognosis.
Elagolix 150mg: suppresses lesions 50%, delays infertility progression.
Progestins (desogestrel): 60% amenorrhea, preserves ovarian reserve for fertility.
Aromatase inhibitors + OCP: 55% cyst reduction, better IVF outcomes.
Levonorgestrel-IUS: 70% endometrial suppression, 30% spontaneous pregnancy post-removal.
Danazol short-term: 50% lesion regression, fertility rate 40% post-treatment.
Combined OCP continuous: reduces recurrence 45%, aids fertility planning.
Cabergoline adjunct: prevents adhesion post-op, 35% higher pregnancy.
Pentoxifylline 400mg tid: improves IVF success 15% via anti-inflammatory.
Omega-3 supplementation: 25% lower dysmenorrhea, better fertility prognosis.
N-acetyl cysteine 600mg: cyst size reduction 20%, preserves fertility.
Long-term prognosis: 50% of treated women conceive naturally within 2 years.
Relugolix combo: 75% lesion reduction, minimal bone loss, fertility deferral.
Melatonin 3mg: antioxidant, 30% improved oocyte quality in IVF.
Curcumin 500mg: reduces inflammation markers 40%, aids fertility.
Post-treatment recurrence 20-40% at 5 years with medical therapy.
Dienogest vs GnRH: similar efficacy, better fertility preservation.
Lifestyle (diet/exercise): 15% fertility improvement in mild cases.
Acupuncture adjunct: 20% higher pregnancy rates post-treatment.
Immunomodulators (lupron + steroids): 50% deep lesion shrinkage.
Prognosis after 40: 20% natural conception with medical optimization.
Vitamin D supplementation: corrects deficiency in 70%, improves IVF 10%.

Medical Management and Prognosis Interpretation

While the Endometriosis Infertility battlefield offers a diverse and sometimes promising arsenal—where everything from pharmaceutical sharpshooters to nutritional foot soldiers can improve the odds—the ultimate takeaway is that a tailored, multi-pronged strategy significantly stacks the deck, with half of the treated troops achieving a natural conception within two years.

Prevalence and Demographics

Approximately 30-50% of women with endometriosis experience infertility, with endometriosis accounting for 25-40% of female infertility cases.
In a cohort of 1,236 women with endometriosis, 40% presented with infertility as the primary complaint.
Endometriosis is found in 24-50% of women undergoing laparoscopy for infertility evaluation.
Among infertile women, the prevalence of minimal/mild endometriosis is 17%, moderate/severe is 23%.
Endometriosis affects 10% of reproductive-age women, but up to 50% of those with infertility.
In a meta-analysis of 23 studies, pooled prevalence of endometriosis in infertile women was 25% (95% CI: 19-32%).
African American women with endometriosis have higher infertility rates at 44% compared to 30% in Caucasians.
Endometriosis-related infertility affects 176 million women worldwide annually.
In subfertile women under 35, endometriosis prevalence is 32% via laparoscopy.
35% of women with deep infiltrating endometriosis report infertility.
Infertility rates rise to 67% in stage III/IV endometriosis per ASRM classification.
In a UK study of 5,000 infertile couples, 12% had endometriosis diagnosed.
Adolescent girls with endometriosis show 20% infertility risk by early adulthood.
Endometriosis prevalence in women with pelvic pain and infertility is 40-60%.
In Italian cohort, 28.5% of infertile women had endometriosis.
Global estimate: 190 million women have endometriosis, 40% infertile.
In PCOS-overlap with endometriosis, infertility jumps to 55%.
Nulliparous women with endometriosis have 45% infertility rate.
In Asia, endometriosis infertility prevalence is 15-20% of cases.
US data: 1 in 10 women with endometriosis seek infertility treatment.
Stage I endometriosis linked to 10-15% reduced fecundity in infertile women.
European studies show 30% infertility in endometriosis patients aged 25-35.
In Brazilian study of 400 women, 38% with endometriosis were infertile.
Hispanic women with endometriosis have 35% infertility prevalence.
Overweight BMI (>25) in endometriosis doubles infertility risk to 50%.
Family history of endometriosis increases infertility odds by 2.5-fold to 40%.
In vitro diagnostics show 25% endometriosis in unexplained infertility.
Australian data: 1 in 8 infertile women have endometriosis.
Peritoneal fluid analysis in 500 infertile: 29% endometriosis positive.
Canadian registry: 22% of IVF cycles for endometriosis infertility.

Prevalence and Demographics Interpretation

While endometriosis is often dismissed as just 'bad cramps,' its role as a ruthless saboteur of fertility is clear from the data, which shows it is the uninvited guest lurking behind roughly one in three infertility cases and drastically alters the reproductive potential of millions worldwide.

Surgical Interventions

Laparoscopic excision of endometriosis improves natural pregnancy rates to 60% post-op.
Ablation vs excision: excision yields 75% pain relief and 50% fertility improvement.
Deep infiltrating endometriosis (DIE) surgery: 52% spontaneous pregnancy rate within 1 year.
Cystectomy for endometriomas >4cm: recurrence 20%, fertility preserved in 70%.
Rectovaginal endometriosis resection: 40% achieve pregnancy without ART.
Microsurgical adhesiolysis increases tubal patency to 65%, pregnancy 30%.
Robotic-assisted laparoscopy for stage IV: 55% fertility rate post-op.
Bowel resection in DIE: complication rate 10%, pregnancy rate 45%.
Ureterolysis during endometriosis surgery restores function in 85%, aids fertility.
Hysteroscopic metroplasty for T-shaped uterus in endometriosis: 50% term delivery.
Salpingectomy for hydrosalpinx in endometriosis: IVF success up 25% post-op.
Segmental resection for colorectal endometriosis: 60% dyspareunia relief, 35% pregnancy.
Laparoscopic uterosacral ligament resection: 70% pain reduction, fertility benefit 40%.
Oophorectomy avoidance in unilateral endometrioma: preserves fertility in 80%.
Nerve-sparing radical excision: maintains ovarian reserve, AMH drop <10%.
Postoperative adhesion prevention with barriers: reduces reoperation 30%.
Fertility-sparing cystectomy: recurrence 15% at 2 years, 65% conception rate.
Multidisciplinary DIE surgery: 50% live birth rate in 2 years follow-up.
Vaporization of ovarian endometriomas: preserves AMH better, pregnancy 45%.
Shaving technique for DIE: 55% spontaneous pregnancies.
Secondary surgery after initial laparoscopy: 30% additional fertility gain.
Plasma energy for peritoneal lesions: 60% fertility improvement.
Hysterectomy with BSO avoided: 75% maintain fertility potential post-conservative surgery.
Ileocecal resection: 40% pregnancy rate, low morbidity 8%.
Postoperative GnRH analogs: enhance pregnancy rates by 20% after surgery.

Surgical Interventions Interpretation

The data reveals that while endometriosis is a formidable thief of fertility, skillful and meticulously chosen surgical intervention can be a powerful counter-thief, often restoring a hopeful path to parenthood from a landscape of pain and obstruction.

Sources & References

Logos provided by Logo.dev